Nutriband Reports Revenue Increase to $667,432 but Net Loss Narrows in Latest Quarter

Nutriband Inc. reported its financial results for the three months ending April 30, 2025, revealing a revenue of $667,432, a significant increase from $408,532 in the same period last year. The company’s gross profit for the quarter was $251,981, compared to $164,786 in the prior year, reflecting improved margins primarily due to a favorable sales mix. Despite the increase in revenue, Nutriband incurred a net loss of $1,388,869, or $(0.12) per share, which is an improvement from the net loss of $1,898,077, or $(0.21) per share, reported in the previous year.

The company’s total assets decreased to $6,152,181 as of April 30, 2025, down from $7,469,955 at the end of January 2025. This decline was primarily attributed to a reduction in cash and cash equivalents, which fell to $2,964,097 from $4,311,719. Working capital also decreased to $2,504,596 from $3,811,420. The decrease in cash was largely due to operational cash outflows, which amounted to $1,336,972 for the quarter, reflecting ongoing investments in research and development, particularly for the Aversa Fentanyl product.

In terms of strategic developments, Nutriband has focused on enhancing its product offerings and operational capabilities. The company signed an addendum to its agreement with Kindeva Drug Delivery to formalize their partnership for the development of the Aversa Fentanyl product. This partnership is expected to streamline the manufacturing process and support the clinical studies necessary for FDA approval. Additionally, Nutriband completed an equity financing round in April 2024, raising $8,400,000 from European investors, which has bolstered its financial position.

Operationally, Nutriband's customer base remains concentrated in the United States, with no reported sales from its 4P Therapeutics segment during the current quarter due to a strategic shift. The company has also seen a reduction in research and development expenses, which totaled $683,426 for the quarter, down from $974,535 in the previous year, indicating a potential realignment of its development focus. The company’s employee headcount remains stable, with ongoing efforts to enhance its internal accounting capabilities to address previously identified weaknesses in its financial reporting processes.

Looking ahead, Nutriband management expressed optimism about its ability to generate sufficient funds from operations to support its activities over the next twelve months. The company continues to navigate the challenges of product development and regulatory approval processes while aiming to leverage its partnerships and recent financing to enhance its market position. However, the ongoing need for capital and the inherent risks associated with drug development remain critical factors that could impact its future performance.